Actinium Pharmaceuticals, Inc. (ATNM)
Largest Insider Buys in Sector
ATNM Stock Price History Chart
ATNM Stock Performance
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers …
Insider Activity of Actinium Pharmaceuticals, Inc.
Over the last 12 months, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Actinium Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $4,372 was made by SETH SANDESH (Chairman & CEO) on 2018‑12‑10.
List of Insider Buy and Sell Transactions, Actinium Pharmaceuticals, Inc.
| 2018-12-10 | Chairman & CEO | 10,000 0.0095% | $0.44 | $4,372 | -37.79% | |||
| 2018-12-10 | Principal Financial Officer | 10,000 0.0095% | $0.43 | $4,350 | -37.79% | |||
| 2018-11-19 | Chief Scientific Officer | 10,000 0.01% | $0.45 | $4,499 | -31.69% | |||
| 2018-07-17 | CEO | 10,000 0.0094% | $0.79 | $7,900 | -28.76% | |||
| 2018-06-15 | Principal Financial Officer | 12,000 0.0109% | $0.50 | $6,000 | +14.10% | |||
| 2018-04-19 | Chairman & CEO | 5,000 0.0045% | $0.38 | $1,900 | +50.00% | |||
| 2018-02-28 | director | 22,730 0.0257% | $0.43 | $9,774 | +25.81% | |||
| 2017-08-02 | Chairman & CEO | 33,333 0.0538% | $0.75 | $25,000 | -3.28% | |||
| 2017-08-02 | Executive Vice President | 10,000 0.0161% | $0.75 | $7,500 | -3.28% | |||
| 2017-06-15 | Chairman and CEO | 7,500 0.013% | $1.16 | $8,725 | -45.52% | |||
| 2017-06-15 | Chief Medical Officer | 5,000 0.0083% | $1.11 | $5,550 | -45.52% | |||
| 2017-06-15 | Principal Financial Officer | 3,500 0.0061% | $1.17 | $4,095 | -45.52% | |||
| 2016-12-30 | Executive Chairman | 5,000 0.0104% | $0.88 | $4,400 | +16.57% | |||
| 2016-12-12 | Executive Chairman | 5,000 0.0104% | $0.98 | $4,900 | +5.15% | |||
| 2016-08-31 | Sale | 10 percent owner | 136,853 0.2928% | $1.83 | $251,118 | -34.31% | ||
| 2016-08-30 | Sale | 10 percent owner | 56,074 0.1174% | $1.81 | $101,254 | -33.90% | ||
| 2016-08-29 | Sale | 10 percent owner | 25,000 0.0529% | $1.72 | $42,875 | -28.88% | ||
| 2016-08-26 | Sale | 10 percent owner | 25,000 0.052% | $1.70 | $42,620 | -29.07% | ||
| 2016-08-16 | Sale | 10 percent owner | 5,029 0.0107% | $1.72 | $8,652 | -26.18% | ||
| 2016-08-15 | Sale | 10 percent owner | 4,439 0.0093% | $1.72 | $7,635 | -25.87% |
Insider Historical Profitability
| SETH SANDESH | Chairman & CEO | 153333 0.4922% | $1.79 | 10 | 0 | <0.0001% |
| DAVE KAUSHIK J | CEO and Interim CFO | 88500 0.2841% | $1.79 | 1 | 0 | <0.0001% |
| O'Loughlin Steve | Principal Financial Officer | 35500 0.1139% | $1.79 | 3 | 0 | <0.0001% |
| Shetty Ajit | director | 22730 0.073% | $1.79 | 1 | 0 | +25.81% |
| Nicholson, C. David | director | 15000 0.0481% | $1.79 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $13.38M | 5.74 | 1.71M | +1.01% | +$133,689.42 | <0.0001 | |
| The Vanguard Group | $11.32M | 4.86 | 1.45M | +6.02% | +$642,944.76 | <0.0001 | |
| Geode Capital Management | $4.67M | 2 | 595,720 | +4.59% | +$204,942.45 | <0.0001 | |
| State Street | $4.31M | 1.85 | 550,845 | +8.68% | +$344,543.46 | <0.0001 | |
| Northern Trust | $1.81M | 0.77 | 230,605 | +1.86% | +$32,987.79 | <0.0001 |